Lupuso (Esperanto Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lupuso" in Esperanto language version.

refsWebsite

Global rank Esperanto rank

75doi.org

2^nd place

7^th place

51nih.gov

4^th place

9^th place

21ima-press.net

low place

1,634^th place

6bmj.com

1,226^th place

966^th place

3jrheum.org

low place

3elsevier.com

610^th place

799^th place

3wiley.com

222^nd place

188^th place

2oup.com

485^th place

437^th place

2europepmc.org

8,929^th place

low place

2lww.com

2,769^th place

2,262^nd place

2researchgate.net

120^th place

148^th place

2termedia.pl

low place

1web.archive.org

1^st place

1rheumatolog.ru

low place

7,404^th place

1jamanetwork.com

2,650^th place

2,597^th place

1e-mjm.org

low place

1geetaraibhu.org

low place

1nature.com

234^th place

108^th place

1hjdbulletin.org

low place

1springer.com

274^th place

260^th place

1annualreviews.org

3,867^th place

5,203^rd place

1pnas.org

1,293^rd place

333^rd place

1clinexprheumatol.org

low place

1jimmunol.org

low place

1sagepub.com

731^st place

826^th place

1dustri.com

low place

1mayoclinicproceedings.org

low place

1eymj.org

low place

1sciencedirect.com

149^th place

128^th place

1mediar-press.net

low place

annualreviews.org

Kishimoto, T.; T. Hirano (1988). “Molecular regulation of B lymphocyte response”, The Annual Review of Immunology (en) (6), p. 485–512. doi:10.1146/annurev.iy.06.040188.002413. Alirita 01-09-2020..

bmj.com

ard.bmj.com

Font, J.; L. Pallarés, R. Cervera, A. López-Soto, M. Navarro, X. Bosch, M. Ingelmo (10-1991). “Systemic lupus erythematosus in the elderly: clinical and immunological characteristics”, Annals of the Rheumatic Diseases (en) 50 (10), p. 702–705. doi:10.1136/ard.50.10.702. Alirita 31-08-2020..
Manger, K.; B. Manger, R. Repp, M. Geisselbrecht, A. Geiger, A. Pfahlberg, T. Harrer, J. Kalden (12-2002). “Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus”, Annals of the Rheumatic Diseases (en) 61 (12), p. 1065–1070. doi:10.1136/ard.61.12.1065. Alirita 31-08-2020..
Krishnan, E.; H. B. Hubert (11-2006). “Ethnicity and mortality from systemic lupus erythematosus in the US”, Annals of the Rheumatic Diseases (en) 65 (11), p. 1500–1505. doi:10.1136/ard.2005.040907. Alirita 31-08-2020..
Alarcón, G. S.; J. Calvo-Alén, G. McGwin Jr., A. G. Uribe, S. M. A. Toloza, J. M. Roseman, M. Fernández, B. J. Fessler, L. M. Vilá, C. Ahn, F. K. Tan, J. D. Reveille, LUMINA Study Group (09-2006). “Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time”, Annals of the Rheumatic Diseases (en) 65 (9), p. 1168–1174. doi:10.1136/ard.200X.046896. Alirita 31-08-2020..
Bertsias, George K.; Maria Tektonidou, Zahir Amoura, Martin Aringer, Ingeborg Bajema, Jo H M Berden, John Boletis, Ricard Cervera, Thomas Dörner, Andrea Doria, Franco Ferrario, Jürgen Floege, Frederic A Houssiau, John P A Ioannidis, David A Isenberg, Cees G M Kallenberg, Liz Lightstone, Stephen D Marks, Alberto Martini, Gabriela Moroni, Irmgard Neumann, Manuel Praga, Matthias Schneider, Argyre Starra, Vladimir Tesar, Carlos Vasconcelos, Ronald F van Vollenhoven, Helena Zakharova, Marion Haubitz, Caroline Gordon, David Jayne, Dimitrios T Boumpas; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (2012-11). “Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis”, Annals of Rheumatic Diseases (en) 71 (11), p. 1771–1782. doi:10.1136/annrheumdis-2012-201940. Alirita 2023-03-22..

pmj.bmj.com

Domenech, I.; Aydintug O., Cervera R., et. al. (1992). “Systemic lupus erythematosus in 50 year olds”, Postgraduate Medical Journal (en) (68), p. 440–444. Alirita 31-08-2020..

clinexprheumatol.org

Gröndal, G.; I. Gunnarsson, J. Rönnelid, S. Rogberg, L. Klareskog, I. Lundberg (09/10-2000). “Cytokine production, serum levels and disease activity in systemic lupus erythematosus”, Clinical and Experimental Rheumatology (en) 18 (5), p. 565–570. Alirita 31-08-1987..

doi.org

Лисицына, Т.А.; Кошелева Н.М. (2010). “Антималярийные препараты в терапии системной красной волчанки: прошлое, настоящее, будущее”, Современная ревматология (ru) 4 (2), p. 81. doi:10.14412/1996-7012-2010-608. Alirita 26-08-2020..
Лила, В.А. (2020). “Клинико-лабораторные взаимосвязи у пациентов с различными вариантами течения системной красной волчанки”, Современная ревматология (ru) (1), p. 26. doi:10.14412/1996-7012-2020-1-26-31. Alirita 20-08-2020..
Лила, В.А. (2020). “Клинико-лабораторные взаимосвязи у пациентов с различными вариантами течения системной красной волчанки”, Современная ревматология (ru) (1), p. 26. doi:10.14412/1996-7012-2020-1-26-31. Alirita 20-08-2020..
Клюквина, Н.Г.; Е.А. Ведерникова, Г.В. Ломанова (2013). “Особенности системной красной волчанки у мужчин: описание случаев и данные литературы”, Современная ревматология (ru) 7 (4), p. 26. doi:10.14412/1996-7012-2013-2435. Alirita 20-08-2020..
Лила, А.М.; Трофимов Е.А., Лила В.А. (2015). “Системная красная волчанка: особенности течения у беременных и варианты терапии”, Современная ревматология (ru) 9 (3), p. 44. doi:10.14412/1996-7012-2015-3-43-47. Alirita 20-08-2020..
Клюквина, Н.Г.; Е.А. Ведерникова, Г.В. Ломанова (2013). “Особенности системной красной волчанки у мужчин: описание случаев и данные литературы”, Современная ревматология (ru) 7 (4), p. 27. doi:10.14412/1996-7012-2013-2435. Alirita 20-08-2020..
Лила, В.А. (2020). “Клинико-лабораторные взаимосвязи у пациентов с различными вариантами течения системной красной волчанки”, Современная ревматология (ru) (1), p. 27. doi:10.14412/1996-7012-2020-1-26-31. Alirita 20-08-2020..
Лила, В.А. (2020). “Клинико-лабораторные взаимосвязи у пациентов с различными вариантами течения системной красной волчанки”, Современная ревматология (ru) 14 (1), p. 29. doi:10.14412/1996-7012-2020-1-26-31. Alirita 20-08-2020..
Hoffman, Glinda S.; Edward L. Treadwell, E. William St. Clair, Gary S. Gilkeson, Mary Anne Dooley (15-08-2007). “Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus”, Arthritis Care & Research (en) 57 (6), p. 993–999. doi:10.1002/art.22894. Alirita 31-08-2020..
Font, J.; L. Pallarés, R. Cervera, A. López-Soto, M. Navarro, X. Bosch, M. Ingelmo (10-1991). “Systemic lupus erythematosus in the elderly: clinical and immunological characteristics”, Annals of the Rheumatic Diseases (en) 50 (10), p. 702–705. doi:10.1136/ard.50.10.702. Alirita 31-08-2020..
Boddaert, Jacques; Du Le Thi Huong, Zahir Amoura, Bertrand Wechsler, Pierre Godeau, Jean-Charles Piette (11-2004). “Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature”, Medicine (Baltimore) (en) 83 (6), p. 348–359. doi:10.1097/01.md.0000147737.57861.7c. Alirita 27-08-2020..
Maddock Jr., Robert K. (11-01-1965). “Incidence of Systemic Lupus Erythematosus by Age and Sex”, JAMA (en) 191 (2), p. 137–138. doi:10.1001/jama.1965.03080020065026. Alirita 31-08-2020..
Mak, S. K.; E. K. Lam, A. K. Wong (20-05-2002). “Clinical profile of patients with late-onset SLE: not a benign subgroup”, Lupus (en) 7 (1), p. 23–28. doi:10.1191/096120398678919723. Alirita 31-08-2020..
Wilson, H. A.; M. E. Hamilton, D. A. Spyker, C. M. Brunner, W. M. o'Brien, J. S. Davis 4th, J. B. Winfield (10-1981). “Age influences the clinical and serologic expression of systemic lupus erythematosus”, Arthritis & Rheumatology (en) 24 (10), p. 1230–1235. doi:10.1002/art.1780241002. Alirita 31-08-2020..
Medlin, Jennifer L.; Karen E. Hansen, Sara R. Fitz, Christie M. Bartels (06-2016). “A Systematic Review and Meta-Analysis of Cutaneous Manifestations in Late Versus Early-Onset Systemic Lupus Erythematosus”, Seminars in Arthritis and Rheumatism (en) 45 (6), p. 691–697.. doi:10.1016/j.semarthrit.2016.01.004. Alirita 31-08-2020..
Manoussakis, Menelaos N.; Chryssoula Georgopoulou, Elias Zintzaras, Marilyn Spyropoulou, Aikaterini Stavropoulou, Fotini N. Skopouli, Haralampos M. Moutsopoulos (03-2004). “Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome”, Arthritis & Rheumatology (en) 50 (3), p. 882–891. doi:10.1002/art.20093. Alirita 31-08-2020..
Cervera, R.; Munther A. Khamashta, Josep Font, Gian Domenico Sebastiani, Antonio Gil, Paz Lavilla, Juan Carlos Mejía, A. Olcay Aydintug, Hanna Chwalinska-Sadowska, Enrique de Ramón, Antonio Fernández-Nebro, Mauro Galeazzi, Merete Valen, Alessandro Mathieu, Frédéric Houssiau, Natividad Caro, Paula Alba, Manuel Ramos-Casals, Miguel Ingelmo, Graham R. V. Hughes, European Working Party on Systemic Lupus Erythematosus (09-2003). “Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients”, Medicine (Baltimore) (en) 85 (5), p. 299–308. doi:10.1097/01.md.0000091181.93122.55. Alirita 31-08-2020..
Manger, K.; B. Manger, R. Repp, M. Geisselbrecht, A. Geiger, A. Pfahlberg, T. Harrer, J. Kalden (12-2002). “Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus”, Annals of the Rheumatic Diseases (en) 61 (12), p. 1065–1070. doi:10.1136/ard.61.12.1065. Alirita 31-08-2020..
Ward, M. M.; E. Pyun, S. Studenski (10-1995). “Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort”, Arthritis & Rheumatology (en) 38 (10), p. 1492–1499. doi:10.1002/art.1780381016. Alirita 31-08-2020..
Hochberg, R. W. (12-1987). “Mortality from systemic lupus erythematosus in England and Wales, 1974-1983”, Rheumatology (en) 26 (6), p. 437–441. doi:10.1093/rheumatology/26.6.437. Alirita 31-08-2020..
Bertoli, A.M.; Vilá L.M., Reveille J.D., Alarcón G.S., LUMINA Study Group, Sanchez M.L., Liu J.M., Apte M., Sowell E., Pinilla-Diaz C., Sandoval R. (01-11-2008). “Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage”, The Journal of Rheumatology (en) 35 (12), p. 2355–2358. doi:10.3899/jrheum.080175. Alirita 31-08-2020..
Pu, S. J.; S. F. Luo, Y. J. Wu, H. S. Cheng, H. H. Ho (2000). “The clinical features and prognosis of lupus with disease onset at age 65 and older”, Lupus (en) 9 (2), p. 96–100. doi:10.1191/096120300678828109. Alirita 31-08-2020..
Goobie, Gillian C.; Sasha Bernatsky, Rosalind Ramsey-Goldman, Ann E. Clarke (09-2015). “Malignancies in Systemic Lupus Erythematosus – a 2015 Update”, Current Opinion in Rheumatology (en) 27 (5), p. 454–460. doi:10.1097/BOR.0000000000000202. Alirita 31-08-2020..
Draborg, Anette Holck; Karen Duus, and Gunnar Houen (2013). “Epstein-Barr Virus in Systemic Autoimmune Diseases”, Clinical & Developmental Immunology (en). doi:10.1155/2013/535738. Alirita 31-08-2020..
Rai, Richa; Sudhir Kumar Chauhana, Vikas Vikram Singha, Madhukar Rai, Geeta Rai (03-2015). “Heat shock protein 27 and its regulatory molecules express differentially in SLE patients with distinct autoantibody profiles”, Immunology Letters (en) 164 (1), p. 25–32. doi:10.1016/j.imlet.2015.01.007. Alirita 31-08-2020..
Grzegrzolka, Jedrzej; Krzysztof Kurnol, Paweł Piotrów, Bartosz Pula (12-2012). “Hsp-27 Expression in Invasive Ductal Breast Carcinoma”, Folia Histochemica et Cytobiologica (en) 50 (5), p. 527–533. doi:10.5603/16717. Alirita 31-08-2020..
Tomic-Lucic, Aleksandra; Radmila Petrovic, Marija Radak-Perovic, Dragan Milovanovic, Jasmina Milovanovic, Sandra Zivanovic, Suzana Pantovic, Mirjana Veselinovic (07-2013). “Late-onset systemic lupus erythematosus: clinical features, course, and prognosis”, Clinical Rheumatology (en) 32 (7), p. 1053–1058. doi:10.1007/s10067-013-2238-y. Alirita 31-08-2020..
Tomic-Lucic, Aleksandra; Radmila Petrovic, Marija Radak-Perovic, Dragan Milovanovic, Jasmina Milovanovic, Sandra Zivanovic, Suzana Pantovic, Mirjana Veselinovic (2007). “Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment”, Drugs & Aging (en) 24 (9), p. 701–715. doi:10.2165/00002512-200724090-00001. Alirita 31-08-2020..
Krishnan, E.; H. B. Hubert (11-2006). “Ethnicity and mortality from systemic lupus erythematosus in the US”, Annals of the Rheumatic Diseases (en) 65 (11), p. 1500–1505. doi:10.1136/ard.2005.040907. Alirita 31-08-2020..
Alarcón, G. S.; J. Calvo-Alén, G. McGwin Jr., A. G. Uribe, S. M. A. Toloza, J. M. Roseman, M. Fernández, B. J. Fessler, L. M. Vilá, C. Ahn, F. K. Tan, J. D. Reveille, LUMINA Study Group (09-2006). “Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time”, Annals of the Rheumatic Diseases (en) 65 (9), p. 1168–1174. doi:10.1136/ard.200X.046896. Alirita 31-08-2020..
Alarcón-Segovia, Donato; Marta E. Alarcón-Riquelme, Mario H. Cardiel, Francisco Caeiro, Loreto Massardo, Antonio R. Villa, Bernardo A. Pons-Estel, Grupo Latinoamericano de Estudio del Lupus Eritematoso (GLADEL) (04-2005). “Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort”, Arthritis & Rheumatology (en) 52 (4), p. 1138–1147. doi:10.1002/art.20999. Alirita 31-08-2020..
Wong, Maida; Betty P. Tsao (10-2006). “Current topics in human SLE genetics”, Seminars in Immunopathology (en) 28 (2), p. 97–107. doi:10.1007/s00281-006-0031-6. Alirita 31-08-2020..
Pan, Chi-Feng; Chien-Jang Wu, Han Hsiang Chen, C. W. Dang (02-2009). “Molecular analysis of HLA-DRB1 allelic associations with systemic lupus erythematous and lupus nephritis in Taiwan”, Lupus (en) 18 (8), p. 698–704. doi:10.1177/0961203308101955. Alirita 31-08-2020..
Клюквина, Н.Г. (4-2017). “Особенности системной красной волчанки с дебютом в пожилом возрасте”, Современная ревматология (ru), p. 9. doi:10.1177/0961203308101955. Alirita 31-08-2020..
Клюквина, Н.Г. (2015). “Системная красная волчанка и в и тамин D”, Современная ревматология (ru) 9 (2), p. 57–65. doi:10.14412/1996-7012-2015-2-57-65. Alirita 31-08-2020..
Illei, Gabor G.; Yuko Shirota, Cheryl H. Yarboro, Jimmy Daruwalla, Edward Tackey, Kazuki Takada, Thomas Fleisher, James E. Balow, Peter E. Lipsky (20-2010). “Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study”, Arthritis & Rheumatology (en) 62 (2), p. 542–552. doi:10.1002/art.27221. Alirita 31-08-2020..
Kishimoto, T.; T. Hirano (1988). “Molecular regulation of B lymphocyte response”, The Annual Review of Immunology (en) (6), p. 485–512. doi:10.1146/annurev.iy.06.040188.002413. Alirita 01-09-2020..
Kang, Sujin; Toshio Tanaka, Tadamitsu Kishimoto (01-2015). “Therapeutic uses of anti-interleukin-6 receptor antibody”, International Immunology (en) 27 (1), p. 21–29. doi:10.1093/intimm/dxu081. Alirita 01-09-2020..
Gauldie, J.; C. Richards, D. Harnish, P. Lansdorp, H. Baumann (10-1987). “Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells”, Proceedings of the National Academy of Sciences of the United States of America (en) 84 (20), p. 7251–7255. doi:10.1073/pnas.84.20.7251. Alirita 01-09-2020..
Andus, T.; T. Geiger, T. Hirano, H. Northoff, U. Ganter, J. Bauer, T. Kishimoto, P. C. Heinrich (10-1987). “Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells”, FEBS Letters (en) 221 (1), p. 18–22. doi:10.1016/0014-5793(87)80344-7. Alirita 31-08-1987..
Chun, Hye-Young; Jae-Wook Chung, Hyoun-Ah Kim, Jeong-Moon Yun, Ja-Young Jeon, Young-Min Ye, Seung-Hyun Kim, Hae-Sim Park, Chang-Hee Suh (09-2007). “Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus”, The Journal of Clinical Immunology (en) 27 (5), p. 461–466. doi:10.1007/s10875-007-9104-0. Alirita 31-08-1987..
Peterson, E.; Robertson, W. Emlen (01-12-1996). “Serum and urinary interleukin-6 in systemic lupus erythematosus”, Lupus (en) 5 (6), p. 571–575. doi:10.1177/096120339600500603. Alirita 31-08-1987..
Klashman, D. J.; R. A. Martin, O. Martínez-Maza, R. H. Stevens (03-1991). “In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells”, Arthritis & Rheumatology (en) 34 (3), p. 276–286. doi:10.1002/art.1780340305. Alirita 31-08-1987..
Tsai, C. Y.; T. H. Wu, C. L. Yu, J. Y. Lu, Y. Y. Tsai (07-2000). “Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis”, Nephron (en) 85 (3), p. 207–214. doi:10.1159/000045663. Alirita 31-08-1987..
Moder, K. G.; T. D. Miller, H. D. Tazelaar (03-1999). “Cardiac involvement in systemic lupus erythematosus”, Mayo Clinic Proceedings (en) 74 (3), p. 275–84. doi:10.4065/74.3.275. Alirita 31-08-1987..
Makol, Ashima; Lawrence E. Gibson, Clement J. Michet (03-2012). “Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis”, JCR: Journal of Clinical Rheumatology (en) 18 (2), p. 92–95. doi:10.1097/RHU.0b013e31823ecd73. Alirita 31-08-1987..
García-Hernández, Francisco J.; Rocío González-León, María J. Castillo-Palma, Celia Ocaña-Medina, Julio Sánchez-Román (10-2012). “Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus”, Rheumatology (en) 15 (10), p. 1918–1919. doi:10.1093/rheumatology/kes072. Alirita 31-08-1987..
Соловьев, С.К.; Меснянкина А.А., Каратеев Д.Е., Лучихина Е.Л., Сигидин Я.А., Асеева Е.А., Елонаков А.В., Насонов Е.Л. (2017). “Эффективность терапии тоцилизумабом обострения системной красной волчанки. Описание случая и обзор литературы”, Современная ревматология (ru) 11 (3), p. 85–90. doi:10.14412/1996-7012-2017-3-85-90. Alirita 31-08-1987..
Bastian, H. M.; J. M. Roseman, G. McGwin Jr., G. S. Alarcón, A. W. Friedman, B. J. Fessler, B. A. Baethge, J. D. Reveille (2002). “Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis”, Lupus (en) 11 (3), p. 152–160. doi:10.1191/0961203302lu158oa. Alirita 2023-03-17..
Jakes, Rupert W.; Sang-Cheol Bae, Worawit Louthrenoo, Chi-Chiu Mok, Sandra V. Navarra, Namhee Kwon (2012-02). “Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality”, Arthritis Care & Research (en) 64 (2), p. 159–168. doi:10.1002/acr.20683. Alirita 2023-03-17..
Краснова, Т. Н. (2008). “Поражение почек при системной красной волчанке: современные представления о патогенезе, клинике, подходы к лечению”, Современная ревматология (ru) 2 (3), p. 18–19. doi:10.14412/1996-7012-2008-483. Alirita 2023-03-20..
Краснова, Т. Н. (2008). “Поражение почек при системной красной волчанке: современные представления о патогенезе, клинике, подходы к лечению”, Современная ревматология (ru) 2 (3), p. 18–19. doi:10.14412/1996-7012-2008-483. Alirita 2023-03-20..
Wakasugi, Daisuke; Takahisa Gono, Yasushi Kawaguchi, Masako Hara, Yumi Koseki, Yasuhiro Katsumata, Masanori Hanaoka, Hisashi Yamanaka (2012-01). “Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures” (en) 39 (1), p. 79–85. doi:10.3899/jrheum.110532. Alirita 2023-03-17..
Olson, Stephen W.; Jessica J Lee, Lisa K Prince, Thomas P Baker, Patricia Papadopoulos, Jess Edison, Kevin C Abbott (2013-10). “Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis”, Clinical Nephrology (en) 8 (10), p. 1702–1708. doi:10.2215/CJN.01910213. Alirita 2023-03-17..
Stojan, G.; M Petri (2016-07). “Anti-C1q in systemic lupus erythematosus”, Lupus (en) 25 (8), p. 873–877. doi:10.1177/0961203316645205. Alirita 2023-03-17..
Weixin, Hu; Yinghua Chen, Shaofan Wang, Hao Chen, Zhengzhao Liu, Caihong Zeng, Haitao Zhang, Zhihong Liu (2016-04-07). “Clinical-Morphological Features and Outcomes of Lupus Podocytopathy”, Clinical Nephrology (en) 11 (4), p. 585–592. doi:10.2215/CJN.06720615. Alirita 2023-03-17..
Di, Song; Li-hua Wu, Feng-mei Wang, Xiao-wei Yang, Di Zhu, Min Chen, Feng Yu, Gang Liu, Ming-hui Zhao (2013-01-15). “The spectrum of renal thrombotic microangiopathy in lupus nephritis”, Arthritis research & therapy (en) 15 (1). doi:10.1186/ar4142. Alirita 2023-03-17..
Bernatsky, S.; J-F Boivin, L Joseph, S Manzi, E Ginzler, D D Gladman, M Urowitz, P R Fortin, M Petri, S Barr, C Gordon, S-C Bae, D Isenberg, A Zoma, C Aranow, M-A Dooley, O Nived, G Sturfelt, K Steinsson, G Alarcón, J-L Senécal, M Zummer, J Hanly, S Ensworth, J Pope, S Edworthy, A Rahman, J Sibley, H El-Gabalawy, T McCarthy, Y St Pierre, A Clarke, R Ramsey-Goldman (2006 (Aŭgusto)). “Mortality in systemic lupus erythematosus”, Arthritis & Rheumatology (en) 54 (8). doi:10.1002/art.21955. Alirita 2023-03-17..
Краснова, Т. Н. (2008). “Поражение почек при системной красной волчанке: современные представления о патогенезе, клинике, подходы к лечению”, Современная ревматология 2 (3), p. 21. doi:10.14412/1996-7012-2008-483. Alirita 2023-03-20..
Bertsias, George K.; Maria Tektonidou, Zahir Amoura, Martin Aringer, Ingeborg Bajema, Jo H M Berden, John Boletis, Ricard Cervera, Thomas Dörner, Andrea Doria, Franco Ferrario, Jürgen Floege, Frederic A Houssiau, John P A Ioannidis, David A Isenberg, Cees G M Kallenberg, Liz Lightstone, Stephen D Marks, Alberto Martini, Gabriela Moroni, Irmgard Neumann, Manuel Praga, Matthias Schneider, Argyre Starra, Vladimir Tesar, Carlos Vasconcelos, Ronald F van Vollenhoven, Helena Zakharova, Marion Haubitz, Caroline Gordon, David Jayne, Dimitrios T Boumpas; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (2012-11). “Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis”, Annals of Rheumatic Diseases (en) 71 (11), p. 1771–1782. doi:10.1136/annrheumdis-2012-201940. Alirita 2023-03-22..
Панафидина, Т.А.; Попкова Т.В. (2018). “Общие принципы лечения волчаночного нефрита с профилактикой сердечно-сосудистых осложнений”, Современная ревматологи (ru) 12 (4), p. 7–8. doi:10.14412/1996-7012-2018-4-4-8. Alirita 2023-03-22..
Файззулина, Д.Л.; Шпрах В.В., Калягин А.Н. (2012). “Особенности цереброваскулярной патологии при системной красной волчанке”, Современная ревматология (ru) 6 (2), p. 25. doi:10.14412/1996-7012-2012-724. Alirita 20-08-2020..
Ellis, S. G.; M. A. Verity (02-1979). “Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955-1977”, Seminars in Arthritis and Rheumatism (en) 8 (3), p. 212–221. doi:10.1016/s0049-0172(79)80009-8. Alirita 20-08-2020..
Westerman, Eric M.; Janet M. Miles, Miroslav Backonja, Walter R. Sundstrom (09-1992). “Neuropathologic findings in multi‐infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event”, Folia Neuropathologica (en) 35 (9), p. 1038–1041. doi:10.1002/art.1780350908. Alirita 20-08-2020..
Coull, Bruce M.; Scott H. Goodnight (09-1990). “Antiphospholipid Antibodies, Prethrombotic States, and Stroke”, Stroke (en) 21 (9), p. 1370–1374. doi:10.1161/01.str.21.9.1370. Alirita 20-08-2020..
Coull, Bruce M.; Scott H. Goodnight (31-12-2007). “Antiphospholipid Syndrome and Vascular Ischemic (Occlusive) Diseases: An Overview”, Yonsei Medical Journal (en) 48 (6), p. 1370–1374. doi:10.3349/ymj.2007.48.6.901. Alirita 20-08-2020..
Asherson, Ronald A.; Ronald H.W.M. Derksen, Nigel Harris Phil, Bonno N.Bouma, Azzudin E. Gharavi, LouisKater, Graham R.V.Hughes (05-1987). “Chorea in systemic lupus erythematosus and “lupus-like” disease: Association with antiphospholipid antibodies”, Seminars in Arthritis and Rheumatism (en) 16 (4), p. 253–259. doi:10.1016/0049-0172(87)90003-5. Alirita 20-08-2020..
Файззулина, Д.Л.; Шпрах В.В., Калягин А.Н. (2012). “Особенности цереброваскулярной патологии при системной красной волчанке”, Современная ревматология (ru) 6 (2), p. 26. doi:10.14412/1996-7012-2012-724. Alirita 20-08-2020..
Файззулина, Д.Л.; Шпрах В.В., Калягин А.Н. (2012). “Особенности цереброваскулярной патологии при системной красной волчанке”, Современная ревматология (ru) 6 (2), p. 27. doi:10.14412/1996-7012-2012-724. Alirita 20-08-2020..
Hughson, M. D.; G. A. McCarty, R. A. Brumback (2012). “Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome”, Human Pathology (en) 26 (7), p. 716–724. doi:10.1016/0046-8177(95)90218-x. Alirita 20-08-2020..
Файззулина, Д.Л.; Шпрах В.В., Калягин А.Н. (2012). “Особенности цереброваскулярной патологии при системной красной волчанке”, Современная ревматология (ru) 6 (2), p. 28. doi:10.14412/1996-7012-2012-724. Alirita 20-08-2020..
Файззулина, Д.Л.; Шпрах В.В., Калягин А.Н. (2012). “Особенности цереброваскулярной патологии при системной красной волчанке”, Современная ревматология (ru) 6 (2), p. 30. doi:10.14412/1996-7012-2012-724. Alirita 20-08-2020..
Соловьев, С. К.; Е. А. Асеева, Т. В. Попкова, Н. Г. Клюквина, Т. М. Решетняк, Т. А. Лисицына, Н. М. Кошелева, М. Э. Цанян, А. А. Меснянкина, Т. А. Панафидина, Л. В. Кондратьева, Н. В. Середавкина, E. В. Герасимова (2015). “Стратегия лечения системной красной волчанки «до достижения цели» (Treat-to-Target SLE). Pекомендации международной рабочей группы и комментарии российских экспертов”, Научно-практическая ревматология (ru) 53 (1), p. 9–16. doi:10.14412/1995-4484-2015-9-16. Alirita 08-09-2020..
Воробьева, Л.Д.; Асеева Е.А. (2017). “Значение качества жизни, связанного со здоровьем, у больных системной красной волчанкой и современные инструменты его оценки”, Современная ревматология (ru) 11 (4). doi:10.14412/1996-7012-2017-4-62-72. Alirita 08-09-2020..
Лила, В.А.; Гунчикова В.М., Новикова А.М. (2009). “Остеопороз при системной красной волчанке”, Современная ревматология (ru) (4), p. 59. doi:10.14412/1996-7012-2009-575. Alirita 26-08-2020..

dustri.com

Iwano, M.; K. Dohi, E. Hirata, N. Kurumatani, Y. Horii, H. Shiiki, A. Fukatsu, T. Matsuda, T. Hirano, T. Kishimoto, et al. (07-1993). “Urinary levels of IL-6 in patients with active lupus nephritis”, Clinical Nephrology (en) 40 (1), p. 16–21. Alirita 31-08-1987..

e-mjm.org

Shaikh, S.K.; F. Wang (03-1995). “Late-onset systemic lupus erythematosus: clinical and immunological characteristics”, Medical Journal of Malaysia (en) 50 (1), p. 25–31. Alirita 31-08-2020..

elsevier.com

journals.elsevier.com

Medlin, Jennifer L.; Karen E. Hansen, Sara R. Fitz, Christie M. Bartels (06-2016). “A Systematic Review and Meta-Analysis of Cutaneous Manifestations in Late Versus Early-Onset Systemic Lupus Erythematosus”, Seminars in Arthritis and Rheumatism (en) 45 (6), p. 691–697.. doi:10.1016/j.semarthrit.2016.01.004. Alirita 31-08-2020..
Ellis, S. G.; M. A. Verity (02-1979). “Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955-1977”, Seminars in Arthritis and Rheumatism (en) 8 (3), p. 212–221. doi:10.1016/s0049-0172(79)80009-8. Alirita 20-08-2020..
Hughson, M. D.; G. A. McCarty, R. A. Brumback (2012). “Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome”, Human Pathology (en) 26 (7), p. 716–724. doi:10.1016/0046-8177(95)90218-x. Alirita 20-08-2020..

europepmc.org

Bertoli, A.M.; Vilá L.M., Reveille J.D., Alarcón G.S., LUMINA Study Group, Sanchez M.L., Liu J.M., Apte M., Sowell E., Pinilla-Diaz C., Sandoval R. (01-11-2008). “Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage”, The Journal of Rheumatology (en) 35 (12), p. 2355–2358. doi:10.3899/jrheum.080175. Alirita 31-08-2020..
Ford, S. E.; Kennedy L., Ford P.M. (01-05-1994). “Clinicopathologic correlations of antiphospholipid antibodies. An autopsy study”, Archives of Pathology & Laboratory Medicine (en) 118 (5), p. 491–495. Alirita 20-08-2020..

eymj.org

Coull, Bruce M.; Scott H. Goodnight (31-12-2007). “Antiphospholipid Syndrome and Vascular Ischemic (Occlusive) Diseases: An Overview”, Yonsei Medical Journal (en) 48 (6), p. 1370–1374. doi:10.3349/ymj.2007.48.6.901. Alirita 20-08-2020..

geetaraibhu.org

Rai, Richa; Sudhir Kumar Chauhana, Vikas Vikram Singha, Madhukar Rai, Geeta Rai (03-2015). “Heat shock protein 27 and its regulatory molecules express differentially in SLE patients with distinct autoantibody profiles”, Immunology Letters (en) 164 (1), p. 25–32. doi:10.1016/j.imlet.2015.01.007. Alirita 31-08-2020..

hjdbulletin.org

Criswell, Lindsey A. (2008). “The genetic contribution to systemic lupus erythematosus”, Bulletin of the Hospital for Joint Diseases (en) 66 (3), p. 176–183. Alirita 31-08-2020..

ima-press.net

mrj.ima-press.net

Лисицына, Т.А.; Кошелева Н.М. (2010). “Антималярийные препараты в терапии системной красной волчанки: прошлое, настоящее, будущее”, Современная ревматология (ru) 4 (2), p. 81. doi:10.14412/1996-7012-2010-608. Alirita 26-08-2020..
Лила, В.А. (2020). “Клинико-лабораторные взаимосвязи у пациентов с различными вариантами течения системной красной волчанки”, Современная ревматология (ru) (1), p. 26. doi:10.14412/1996-7012-2020-1-26-31. Alirita 20-08-2020..
Лила, В.А. (2020). “Клинико-лабораторные взаимосвязи у пациентов с различными вариантами течения системной красной волчанки”, Современная ревматология (ru) (1), p. 26. doi:10.14412/1996-7012-2020-1-26-31. Alirita 20-08-2020..
Клюквина, Н.Г.; Е.А. Ведерникова, Г.В. Ломанова (2013). “Особенности системной красной волчанки у мужчин: описание случаев и данные литературы”, Современная ревматология (ru) 7 (4), p. 26. doi:10.14412/1996-7012-2013-2435. Alirita 20-08-2020..
Лила, А.М.; Трофимов Е.А., Лила В.А. (2015). “Системная красная волчанка: особенности течения у беременных и варианты терапии”, Современная ревматология (ru) 9 (3), p. 44. doi:10.14412/1996-7012-2015-3-43-47. Alirita 20-08-2020..
Клюквина, Н.Г.; Е.А. Ведерникова, Г.В. Ломанова (2013). “Особенности системной красной волчанки у мужчин: описание случаев и данные литературы”, Современная ревматология (ru) 7 (4), p. 27. doi:10.14412/1996-7012-2013-2435. Alirita 20-08-2020..
Лила, В.А. (2020). “Клинико-лабораторные взаимосвязи у пациентов с различными вариантами течения системной красной волчанки”, Современная ревматология (ru) (1), p. 27. doi:10.14412/1996-7012-2020-1-26-31. Alirita 20-08-2020..
Лила, В.А. (2020). “Клинико-лабораторные взаимосвязи у пациентов с различными вариантами течения системной красной волчанки”, Современная ревматология (ru) 14 (1), p. 29. doi:10.14412/1996-7012-2020-1-26-31. Alirita 20-08-2020..
Клюквина, Н.Г. (4-2017). “Особенности системной красной волчанки с дебютом в пожилом возрасте”, Современная ревматология (ru), p. 9. doi:10.1177/0961203308101955. Alirita 31-08-2020..
Клюквина, Н.Г. (2015). “Системная красная волчанка и в и тамин D”, Современная ревматология (ru) 9 (2), p. 57–65. doi:10.14412/1996-7012-2015-2-57-65. Alirita 31-08-2020..
Соловьев, С.К.; Меснянкина А.А., Каратеев Д.Е., Лучихина Е.Л., Сигидин Я.А., Асеева Е.А., Елонаков А.В., Насонов Е.Л. (2017). “Эффективность терапии тоцилизумабом обострения системной красной волчанки. Описание случая и обзор литературы”, Современная ревматология (ru) 11 (3), p. 85–90. doi:10.14412/1996-7012-2017-3-85-90. Alirita 31-08-1987..
Краснова, Т. Н. (2008). “Поражение почек при системной красной волчанке: современные представления о патогенезе, клинике, подходы к лечению”, Современная ревматология (ru) 2 (3), p. 18–19. doi:10.14412/1996-7012-2008-483. Alirita 2023-03-20..
Краснова, Т. Н. (2008). “Поражение почек при системной красной волчанке: современные представления о патогенезе, клинике, подходы к лечению”, Современная ревматология (ru) 2 (3), p. 18–19. doi:10.14412/1996-7012-2008-483. Alirita 2023-03-20..
Краснова, Т. Н. (2008). “Поражение почек при системной красной волчанке: современные представления о патогенезе, клинике, подходы к лечению”, Современная ревматология 2 (3), p. 21. doi:10.14412/1996-7012-2008-483. Alirita 2023-03-20..
Файззулина, Д.Л.; Шпрах В.В., Калягин А.Н. (2012). “Особенности цереброваскулярной патологии при системной красной волчанке”, Современная ревматология (ru) 6 (2), p. 25. doi:10.14412/1996-7012-2012-724. Alirita 20-08-2020..
Файззулина, Д.Л.; Шпрах В.В., Калягин А.Н. (2012). “Особенности цереброваскулярной патологии при системной красной волчанке”, Современная ревматология (ru) 6 (2), p. 26. doi:10.14412/1996-7012-2012-724. Alirita 20-08-2020..
Файззулина, Д.Л.; Шпрах В.В., Калягин А.Н. (2012). “Особенности цереброваскулярной патологии при системной красной волчанке”, Современная ревматология (ru) 6 (2), p. 27. doi:10.14412/1996-7012-2012-724. Alirita 20-08-2020..
Файззулина, Д.Л.; Шпрах В.В., Калягин А.Н. (2012). “Особенности цереброваскулярной патологии при системной красной волчанке”, Современная ревматология (ru) 6 (2), p. 28. doi:10.14412/1996-7012-2012-724. Alirita 20-08-2020..
Файззулина, Д.Л.; Шпрах В.В., Калягин А.Н. (2012). “Особенности цереброваскулярной патологии при системной красной волчанке”, Современная ревматология (ru) 6 (2), p. 30. doi:10.14412/1996-7012-2012-724. Alirita 20-08-2020..
Воробьева, Л.Д.; Асеева Е.А. (2017). “Значение качества жизни, связанного со здоровьем, у больных системной красной волчанкой и современные инструменты его оценки”, Современная ревматология (ru) 11 (4). doi:10.14412/1996-7012-2017-4-62-72. Alirita 08-09-2020..
Лила, В.А.; Гунчикова В.М., Новикова А.М. (2009). “Остеопороз при системной красной волчанке”, Современная ревматология (ru) (4), p. 59. doi:10.14412/1996-7012-2009-575. Alirita 26-08-2020..

jamanetwork.com

Maddock Jr., Robert K. (11-01-1965). “Incidence of Systemic Lupus Erythematosus by Age and Sex”, JAMA (en) 191 (2), p. 137–138. doi:10.1001/jama.1965.03080020065026. Alirita 31-08-2020..

jimmunol.org

Linker-Israeli, M.; R. J. Deans, D. J. Wallace, J. Prehn, T. Ozeri-Chen, J. R. Klinenberg (07-1991). “Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis”, The Journal of Immunology (en) 147 (1), p. 117–123. Alirita 31-08-1987..

jrheum.org

Maddison, Peter; Vernon Farewell, David Isenberg, Cynthia Aranow, Sang-Cheol Bae, Susan Barr, Jill Buyon, Paul Fortin, Ellen Ginzler, Dafna Gladman, John Hanly, Susan Manzi, Ola Nived, Michelle Petri, Rosalind Ramsey-Goldman, Gunnar Sturfelt, Systemic Lupus International Collaborating Clinics (20-05-2002). “The rate and pattern of organ damage in late onset systemic lupus erythematosus”, The Journal of Rheumatology (en) 29 (5), p. 913–917. Alirita 31-08-2020..
Zamber, R. W.; G. Starkebaum, R. L. Rubin, H. F. Martens, M. H. Wener (06-1992). “Drug induced systemic lupus erythematosus due to ophthalmic timolol”, The Journal of Rheumatology (en) 19 (6), p. 977–979. Alirita 31-08-2020..
Lawrence, J. S.; C. L. Martins, G. L. Drake (10-1987). “A family survey of lupus erythematosus. 1. Heritability”, The Journal of Rheumatology (en) 14 (5), p. 913–921. Alirita 31-08-2020..

lww.com

journals.lww.com

Goobie, Gillian C.; Sasha Bernatsky, Rosalind Ramsey-Goldman, Ann E. Clarke (09-2015). “Malignancies in Systemic Lupus Erythematosus – a 2015 Update”, Current Opinion in Rheumatology (en) 27 (5), p. 454–460. doi:10.1097/BOR.0000000000000202. Alirita 31-08-2020..
Makol, Ashima; Lawrence E. Gibson, Clement J. Michet (03-2012). “Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis”, JCR: Journal of Clinical Rheumatology (en) 18 (2), p. 92–95. doi:10.1097/RHU.0b013e31823ecd73. Alirita 31-08-1987..

mayoclinicproceedings.org

Moder, K. G.; T. D. Miller, H. D. Tazelaar (03-1999). “Cardiac involvement in systemic lupus erythematosus”, Mayo Clinic Proceedings (en) 74 (3), p. 275–84. doi:10.4065/74.3.275. Alirita 31-08-1987..

mediar-press.net

rsp.mediar-press.net

Соловьев, С. К.; Е. А. Асеева, Т. В. Попкова, Н. Г. Клюквина, Т. М. Решетняк, Т. А. Лисицына, Н. М. Кошелева, М. Э. Цанян, А. А. Меснянкина, Т. А. Панафидина, Л. В. Кондратьева, Н. В. Середавкина, E. В. Герасимова (2015). “Стратегия лечения системной красной волчанки «до достижения цели» (Treat-to-Target SLE). Pекомендации международной рабочей группы и комментарии российских экспертов”, Научно-практическая ревматология (ru) 53 (1), p. 9–16. doi:10.14412/1995-4484-2015-9-16. Alirita 08-09-2020..

nature.com

Graham, Robert R.; Ward Ortmann, Peter Rodine, Karl Espe, Carl Langefeld, Ethan Lange, Adrienne Williams, Stephanie Beck, Chieko Kyogoku, Kathy Moser, Patrick Gaffney, Peter K Gregersen, Lindsey A. Criswell, John B. Harley & Timothy W. Behrens (04-04-2007). “Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE”, European Journal of Human Genetics (en) (15), p. 823–830. Alirita 31-08-2020..

nih.gov

pubmed.ncbi.nlm.nih.gov

Boddaert, Jacques; Du Le Thi Huong, Zahir Amoura, Bertrand Wechsler, Pierre Godeau, Jean-Charles Piette (11-2004). “Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature”, Medicine (Baltimore) (en) 83 (6), p. 348–359. doi:10.1097/01.md.0000147737.57861.7c. Alirita 27-08-2020..
Maddison, Peter; Vernon Farewell, David Isenberg, Cynthia Aranow, Sang-Cheol Bae, Susan Barr, Jill Buyon, Paul Fortin, Ellen Ginzler, Dafna Gladman, John Hanly, Susan Manzi, Ola Nived, Michelle Petri, Rosalind Ramsey-Goldman, Gunnar Sturfelt, Systemic Lupus International Collaborating Clinics (20-05-2002). “The rate and pattern of organ damage in late onset systemic lupus erythematosus”, The Journal of Rheumatology (en) 29 (5), p. 913–917. Alirita 31-08-2020..
Mak, S. K.; E. K. Lam, A. K. Wong (20-05-2002). “Clinical profile of patients with late-onset SLE: not a benign subgroup”, Lupus (en) 7 (1), p. 23–28. doi:10.1191/096120398678919723. Alirita 31-08-2020..
Shaikh, S.K.; F. Wang (03-1995). “Late-onset systemic lupus erythematosus: clinical and immunological characteristics”, Medical Journal of Malaysia (en) 50 (1), p. 25–31. Alirita 31-08-2020..
Wilson, H. A.; M. E. Hamilton, D. A. Spyker, C. M. Brunner, W. M. o'Brien, J. S. Davis 4th, J. B. Winfield (10-1981). “Age influences the clinical and serologic expression of systemic lupus erythematosus”, Arthritis & Rheumatology (en) 24 (10), p. 1230–1235. doi:10.1002/art.1780241002. Alirita 31-08-2020..
Manoussakis, Menelaos N.; Chryssoula Georgopoulou, Elias Zintzaras, Marilyn Spyropoulou, Aikaterini Stavropoulou, Fotini N. Skopouli, Haralampos M. Moutsopoulos (03-2004). “Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome”, Arthritis & Rheumatology (en) 50 (3), p. 882–891. doi:10.1002/art.20093. Alirita 31-08-2020..
Cervera, R.; M. A. Khamashta, J. Font, G. D. Sebastiani, A. Gil, P. Lavilla, I. Doménech, A. O. Aydintug, A. Jedryka-Góral, E. de Ramón, et al. (03-1993). “Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus”, Medicine (Baltimore) (en) 72 (3), p. 113–24. Alirita 31-08-2020..
Cervera, R.; Munther A. Khamashta, Josep Font, Gian Domenico Sebastiani, Antonio Gil, Paz Lavilla, Juan Carlos Mejía, A. Olcay Aydintug, Hanna Chwalinska-Sadowska, Enrique de Ramón, Antonio Fernández-Nebro, Mauro Galeazzi, Merete Valen, Alessandro Mathieu, Frédéric Houssiau, Natividad Caro, Paula Alba, Manuel Ramos-Casals, Miguel Ingelmo, Graham R. V. Hughes, European Working Party on Systemic Lupus Erythematosus (09-2003). “Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients”, Medicine (Baltimore) (en) 85 (5), p. 299–308. doi:10.1097/01.md.0000091181.93122.55. Alirita 31-08-2020..
Ward, M. M.; E. Pyun, S. Studenski (10-1995). “Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort”, Arthritis & Rheumatology (en) 38 (10), p. 1492–1499. doi:10.1002/art.1780381016. Alirita 31-08-2020..
Zamber, R. W.; G. Starkebaum, R. L. Rubin, H. F. Martens, M. H. Wener (06-1992). “Drug induced systemic lupus erythematosus due to ophthalmic timolol”, The Journal of Rheumatology (en) 19 (6), p. 977–979. Alirita 31-08-2020..
Pu, S. J.; S. F. Luo, Y. J. Wu, H. S. Cheng, H. H. Ho (2000). “The clinical features and prognosis of lupus with disease onset at age 65 and older”, Lupus (en) 9 (2), p. 96–100. doi:10.1191/096120300678828109. Alirita 31-08-2020..
Tomic-Lucic, Aleksandra; Radmila Petrovic, Marija Radak-Perovic, Dragan Milovanovic, Jasmina Milovanovic, Sandra Zivanovic, Suzana Pantovic, Mirjana Veselinovic (07-2013). “Late-onset systemic lupus erythematosus: clinical features, course, and prognosis”, Clinical Rheumatology (en) 32 (7), p. 1053–1058. doi:10.1007/s10067-013-2238-y. Alirita 31-08-2020..
Tomic-Lucic, Aleksandra; Radmila Petrovic, Marija Radak-Perovic, Dragan Milovanovic, Jasmina Milovanovic, Sandra Zivanovic, Suzana Pantovic, Mirjana Veselinovic (2007). “Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment”, Drugs & Aging (en) 24 (9), p. 701–715. doi:10.2165/00002512-200724090-00001. Alirita 31-08-2020..
Alarcón, G. S.; J. Calvo-Alén, G. McGwin Jr., A. G. Uribe, S. M. A. Toloza, J. M. Roseman, M. Fernández, B. J. Fessler, L. M. Vilá, C. Ahn, F. K. Tan, J. D. Reveille, LUMINA Study Group (09-2006). “Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time”, Annals of the Rheumatic Diseases (en) 65 (9), p. 1168–1174. doi:10.1136/ard.200X.046896. Alirita 31-08-2020..
Alarcón-Segovia, Donato; Marta E. Alarcón-Riquelme, Mario H. Cardiel, Francisco Caeiro, Loreto Massardo, Antonio R. Villa, Bernardo A. Pons-Estel, Grupo Latinoamericano de Estudio del Lupus Eritematoso (GLADEL) (04-2005). “Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort”, Arthritis & Rheumatology (en) 52 (4), p. 1138–1147. doi:10.1002/art.20999. Alirita 31-08-2020..
Criswell, Lindsey A. (2008). “The genetic contribution to systemic lupus erythematosus”, Bulletin of the Hospital for Joint Diseases (en) 66 (3), p. 176–183. Alirita 31-08-2020..
Wong, Maida; Betty P. Tsao (10-2006). “Current topics in human SLE genetics”, Seminars in Immunopathology (en) 28 (2), p. 97–107. doi:10.1007/s00281-006-0031-6. Alirita 31-08-2020..
Illei, Gabor G.; Yuko Shirota, Cheryl H. Yarboro, Jimmy Daruwalla, Edward Tackey, Kazuki Takada, Thomas Fleisher, James E. Balow, Peter E. Lipsky (20-2010). “Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study”, Arthritis & Rheumatology (en) 62 (2), p. 542–552. doi:10.1002/art.27221. Alirita 31-08-2020..
Kang, Sujin; Toshio Tanaka, Tadamitsu Kishimoto (01-2015). “Therapeutic uses of anti-interleukin-6 receptor antibody”, International Immunology (en) 27 (1), p. 21–29. doi:10.1093/intimm/dxu081. Alirita 01-09-2020..
Gauldie, J.; C. Richards, D. Harnish, P. Lansdorp, H. Baumann (10-1987). “Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells”, Proceedings of the National Academy of Sciences of the United States of America (en) 84 (20), p. 7251–7255. doi:10.1073/pnas.84.20.7251. Alirita 01-09-2020..
Andus, T.; T. Geiger, T. Hirano, H. Northoff, U. Ganter, J. Bauer, T. Kishimoto, P. C. Heinrich (10-1987). “Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells”, FEBS Letters (en) 221 (1), p. 18–22. doi:10.1016/0014-5793(87)80344-7. Alirita 31-08-1987..
Chun, Hye-Young; Jae-Wook Chung, Hyoun-Ah Kim, Jeong-Moon Yun, Ja-Young Jeon, Young-Min Ye, Seung-Hyun Kim, Hae-Sim Park, Chang-Hee Suh (09-2007). “Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus”, The Journal of Clinical Immunology (en) 27 (5), p. 461–466. doi:10.1007/s10875-007-9104-0. Alirita 31-08-1987..
Gröndal, G.; I. Gunnarsson, J. Rönnelid, S. Rogberg, L. Klareskog, I. Lundberg (09/10-2000). “Cytokine production, serum levels and disease activity in systemic lupus erythematosus”, Clinical and Experimental Rheumatology (en) 18 (5), p. 565–570. Alirita 31-08-1987..
Linker-Israeli, M.; R. J. Deans, D. J. Wallace, J. Prehn, T. Ozeri-Chen, J. R. Klinenberg (07-1991). “Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis”, The Journal of Immunology (en) 147 (1), p. 117–123. Alirita 31-08-1987..
Klashman, D. J.; R. A. Martin, O. Martínez-Maza, R. H. Stevens (03-1991). “In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells”, Arthritis & Rheumatology (en) 34 (3), p. 276–286. doi:10.1002/art.1780340305. Alirita 31-08-1987..
Iwano, M.; K. Dohi, E. Hirata, N. Kurumatani, Y. Horii, H. Shiiki, A. Fukatsu, T. Matsuda, T. Hirano, T. Kishimoto, et al. (07-1993). “Urinary levels of IL-6 in patients with active lupus nephritis”, Clinical Nephrology (en) 40 (1), p. 16–21. Alirita 31-08-1987..
Tsai, C. Y.; T. H. Wu, C. L. Yu, J. Y. Lu, Y. Y. Tsai (07-2000). “Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis”, Nephron (en) 85 (3), p. 207–214. doi:10.1159/000045663. Alirita 31-08-1987..
Moder, K. G.; T. D. Miller, H. D. Tazelaar (03-1999). “Cardiac involvement in systemic lupus erythematosus”, Mayo Clinic Proceedings (en) 74 (3), p. 275–84. doi:10.4065/74.3.275. Alirita 31-08-1987..
Makol, Ashima; Lawrence E. Gibson, Clement J. Michet (03-2012). “Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis”, JCR: Journal of Clinical Rheumatology (en) 18 (2), p. 92–95. doi:10.1097/RHU.0b013e31823ecd73. Alirita 31-08-1987..
Bastian, H. M.; J. M. Roseman, G. McGwin Jr., G. S. Alarcón, A. W. Friedman, B. J. Fessler, B. A. Baethge, J. D. Reveille (2002). “Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis”, Lupus (en) 11 (3), p. 152–160. doi:10.1191/0961203302lu158oa. Alirita 2023-03-17..
Jakes, Rupert W.; Sang-Cheol Bae, Worawit Louthrenoo, Chi-Chiu Mok, Sandra V. Navarra, Namhee Kwon (2012-02). “Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality”, Arthritis Care & Research (en) 64 (2), p. 159–168. doi:10.1002/acr.20683. Alirita 2023-03-17..
Wakasugi, Daisuke; Takahisa Gono, Yasushi Kawaguchi, Masako Hara, Yumi Koseki, Yasuhiro Katsumata, Masanori Hanaoka, Hisashi Yamanaka (2012-01). “Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures” (en) 39 (1), p. 79–85. doi:10.3899/jrheum.110532. Alirita 2023-03-17..
Christopher-Stine, Lisa; Mark Siedner, Janice Lin, Mark Haas, Hemal Parekh, Michelle Petri, Derek M Fine (2007-02). “Renal biopsy in lupus patients with low levels of proteinuria” (en) 34 (2), p. 332–335. Alirita 2023-03-17..
Olson, Stephen W.; Jessica J Lee, Lisa K Prince, Thomas P Baker, Patricia Papadopoulos, Jess Edison, Kevin C Abbott (2013-10). “Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis”, Clinical Nephrology (en) 8 (10), p. 1702–1708. doi:10.2215/CJN.01910213. Alirita 2023-03-17..
Stojan, G.; M Petri (2016-07). “Anti-C1q in systemic lupus erythematosus”, Lupus (en) 25 (8), p. 873–877. doi:10.1177/0961203316645205. Alirita 2023-03-17..
Weixin, Hu; Yinghua Chen, Shaofan Wang, Hao Chen, Zhengzhao Liu, Caihong Zeng, Haitao Zhang, Zhihong Liu (2016-04-07). “Clinical-Morphological Features and Outcomes of Lupus Podocytopathy”, Clinical Nephrology (en) 11 (4), p. 585–592. doi:10.2215/CJN.06720615. Alirita 2023-03-17..
Di, Song; Li-hua Wu, Feng-mei Wang, Xiao-wei Yang, Di Zhu, Min Chen, Feng Yu, Gang Liu, Ming-hui Zhao (2013-01-15). “The spectrum of renal thrombotic microangiopathy in lupus nephritis”, Arthritis research & therapy (en) 15 (1). doi:10.1186/ar4142. Alirita 2023-03-17..
Bernatsky, S.; J-F Boivin, L Joseph, S Manzi, E Ginzler, D D Gladman, M Urowitz, P R Fortin, M Petri, S Barr, C Gordon, S-C Bae, D Isenberg, A Zoma, C Aranow, M-A Dooley, O Nived, G Sturfelt, K Steinsson, G Alarcón, J-L Senécal, M Zummer, J Hanly, S Ensworth, J Pope, S Edworthy, A Rahman, J Sibley, H El-Gabalawy, T McCarthy, Y St Pierre, A Clarke, R Ramsey-Goldman (2006 (Aŭgusto)). “Mortality in systemic lupus erythematosus”, Arthritis & Rheumatology (en) 54 (8). doi:10.1002/art.21955. Alirita 2023-03-17..
Bertsias, George K.; Maria Tektonidou, Zahir Amoura, Martin Aringer, Ingeborg Bajema, Jo H M Berden, John Boletis, Ricard Cervera, Thomas Dörner, Andrea Doria, Franco Ferrario, Jürgen Floege, Frederic A Houssiau, John P A Ioannidis, David A Isenberg, Cees G M Kallenberg, Liz Lightstone, Stephen D Marks, Alberto Martini, Gabriela Moroni, Irmgard Neumann, Manuel Praga, Matthias Schneider, Argyre Starra, Vladimir Tesar, Carlos Vasconcelos, Ronald F van Vollenhoven, Helena Zakharova, Marion Haubitz, Caroline Gordon, David Jayne, Dimitrios T Boumpas; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (2012-11). “Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis”, Annals of Rheumatic Diseases (en) 71 (11), p. 1771–1782. doi:10.1136/annrheumdis-2012-201940. Alirita 2023-03-22..
Ellis, S. G.; M. A. Verity (02-1979). “Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955-1977”, Seminars in Arthritis and Rheumatism (en) 8 (3), p. 212–221. doi:10.1016/s0049-0172(79)80009-8. Alirita 20-08-2020..
Szpak, G. M.; A. Kuczyńska-Zardzewiały, J. Popow (1996). “Brain vascular changes in the case of primary antiphospholipid syndrome”, Folia Neuropathologica (en) 34 (2), p. 92–96. Alirita 20-08-2020..
Coull, Bruce M.; Scott H. Goodnight (09-1990). “Antiphospholipid Antibodies, Prethrombotic States, and Stroke”, Stroke (en) 21 (9), p. 1370–1374. doi:10.1161/01.str.21.9.1370. Alirita 20-08-2020..
Hughson, M. D.; G. A. McCarty, R. A. Brumback (2012). “Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome”, Human Pathology (en) 26 (7), p. 716–724. doi:10.1016/0046-8177(95)90218-x. Alirita 20-08-2020..

ncbi.nlm.nih.gov

Font, J.; L. Pallarés, R. Cervera, A. López-Soto, M. Navarro, X. Bosch, M. Ingelmo (10-1991). “Systemic lupus erythematosus in the elderly: clinical and immunological characteristics”, Annals of the Rheumatic Diseases (en) 50 (10), p. 702–705. doi:10.1136/ard.50.10.702. Alirita 31-08-2020..
Medlin, Jennifer L.; Karen E. Hansen, Sara R. Fitz, Christie M. Bartels (06-2016). “A Systematic Review and Meta-Analysis of Cutaneous Manifestations in Late Versus Early-Onset Systemic Lupus Erythematosus”, Seminars in Arthritis and Rheumatism (en) 45 (6), p. 691–697.. doi:10.1016/j.semarthrit.2016.01.004. Alirita 31-08-2020..
Manger, K.; B. Manger, R. Repp, M. Geisselbrecht, A. Geiger, A. Pfahlberg, T. Harrer, J. Kalden (12-2002). “Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus”, Annals of the Rheumatic Diseases (en) 61 (12), p. 1065–1070. doi:10.1136/ard.61.12.1065. Alirita 31-08-2020..
Goobie, Gillian C.; Sasha Bernatsky, Rosalind Ramsey-Goldman, Ann E. Clarke (09-2015). “Malignancies in Systemic Lupus Erythematosus – a 2015 Update”, Current Opinion in Rheumatology (en) 27 (5), p. 454–460. doi:10.1097/BOR.0000000000000202. Alirita 31-08-2020..
Draborg, Anette Holck; Karen Duus, and Gunnar Houen (2013). “Epstein-Barr Virus in Systemic Autoimmune Diseases”, Clinical & Developmental Immunology (en). doi:10.1155/2013/535738. Alirita 31-08-2020..
Krishnan, E.; H. B. Hubert (11-2006). “Ethnicity and mortality from systemic lupus erythematosus in the US”, Annals of the Rheumatic Diseases (en) 65 (11), p. 1500–1505. doi:10.1136/ard.2005.040907. Alirita 31-08-2020..
Coull, Bruce M.; Scott H. Goodnight (31-12-2007). “Antiphospholipid Syndrome and Vascular Ischemic (Occlusive) Diseases: An Overview”, Yonsei Medical Journal (en) 48 (6), p. 1370–1374. doi:10.3349/ymj.2007.48.6.901. Alirita 20-08-2020..
Levine, S.; Deegan M.J., Futrell N. et al. (1990). “Cerebrovascular and neurological disease associated with antiphospholipid antibodies: 48 cases”, Neurology (en) (40), p. 1181—1189. Alirita 20-08-2020..

oup.com

academic.oup.com

Hochberg, R. W. (12-1987). “Mortality from systemic lupus erythematosus in England and Wales, 1974-1983”, Rheumatology (en) 26 (6), p. 437–441. doi:10.1093/rheumatology/26.6.437. Alirita 31-08-2020..
García-Hernández, Francisco J.; Rocío González-León, María J. Castillo-Palma, Celia Ocaña-Medina, Julio Sánchez-Román (10-2012). “Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus”, Rheumatology (en) 15 (10), p. 1918–1919. doi:10.1093/rheumatology/kes072. Alirita 31-08-1987..

pnas.org

Gauldie, J.; C. Richards, D. Harnish, P. Lansdorp, H. Baumann (10-1987). “Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells”, Proceedings of the National Academy of Sciences of the United States of America (en) 84 (20), p. 7251–7255. doi:10.1073/pnas.84.20.7251. Alirita 01-09-2020..

researchgate.net

Grzegrzolka, Jedrzej; Krzysztof Kurnol, Paweł Piotrów, Bartosz Pula (12-2012). “Hsp-27 Expression in Invasive Ductal Breast Carcinoma”, Folia Histochemica et Cytobiologica (en) 50 (5), p. 527–533. doi:10.5603/16717. Alirita 31-08-2020..
Pan, Chi-Feng; Chien-Jang Wu, Han Hsiang Chen, C. W. Dang (02-2009). “Molecular analysis of HLA-DRB1 allelic associations with systemic lupus erythematous and lupus nephritis in Taiwan”, Lupus (en) 18 (8), p. 698–704. doi:10.1177/0961203308101955. Alirita 31-08-2020..

rheumatolog.ru

Решетняк Т. М. Системная красная волчанка (ruse). La Asocio de Reŭmatologoj de Rusio. Arkivita el la originalo je 2019-09-10. Alirita 2020-08-16 .

sagepub.com

journals.sagepub.com

Peterson, E.; Robertson, W. Emlen (01-12-1996). “Serum and urinary interleukin-6 in systemic lupus erythematosus”, Lupus (en) 5 (6), p. 571–575. doi:10.1177/096120339600500603. Alirita 31-08-1987..

sciencedirect.com

Asherson, Ronald A.; Ronald H.W.M. Derksen, Nigel Harris Phil, Bonno N.Bouma, Azzudin E. Gharavi, LouisKater, Graham R.V.Hughes (05-1987). “Chorea in systemic lupus erythematosus and “lupus-like” disease: Association with antiphospholipid antibodies”, Seminars in Arthritis and Rheumatism (en) 16 (4), p. 253–259. doi:10.1016/0049-0172(87)90003-5. Alirita 20-08-2020..

springer.com

Wong, Maida; Betty P. Tsao (10-2006). “Current topics in human SLE genetics”, Seminars in Immunopathology (en) 28 (2), p. 97–107. doi:10.1007/s00281-006-0031-6. Alirita 31-08-2020..

termedia.pl

Szpak, G. M.; A. Kuczyńska-Zardzewiały, J. Popow (1996). “Brain vascular changes in the case of primary antiphospholipid syndrome”, Folia Neuropathologica (en) 34 (2), p. 92–96. Alirita 20-08-2020..
Westerman, Eric M.; Janet M. Miles, Miroslav Backonja, Walter R. Sundstrom (09-1992). “Neuropathologic findings in multi‐infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event”, Folia Neuropathologica (en) 35 (9), p. 1038–1041. doi:10.1002/art.1780350908. Alirita 20-08-2020..

web.archive.org

Решетняк Т. М. Системная красная волчанка (ruse). La Asocio de Reŭmatologoj de Rusio. Arkivita el la originalo je 2019-09-10. Alirita 2020-08-16 .

wiley.com

onlinelibrary.wiley.com

Hoffman, Glinda S.; Edward L. Treadwell, E. William St. Clair, Gary S. Gilkeson, Mary Anne Dooley (15-08-2007). “Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus”, Arthritis Care & Research (en) 57 (6), p. 993–999. doi:10.1002/art.22894. Alirita 31-08-2020..
Westerman, Eric M.; Janet M. Miles, Miroslav Backonja, Walter R. Sundstrom (09-1992). “Neuropathologic findings in multi‐infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event”, Folia Neuropathologica (en) 35 (9), p. 1038–1041. doi:10.1002/art.1780350908. Alirita 20-08-2020..

febs.onlinelibrary.wiley.com

Andus, T.; T. Geiger, T. Hirano, H. Northoff, U. Ganter, J. Bauer, T. Kishimoto, P. C. Heinrich (10-1987). “Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells”, FEBS Letters (en) 221 (1), p. 18–22. doi:10.1016/0014-5793(87)80344-7. Alirita 31-08-1987..